MicroRNA-9-1(miR-9-1) plays an important role in the mechanism that regulates the lineage fate of differentiating hematopoietic cells. Recent studies have shown that miR-9-1 is downregulated in t (8; 21) AML. However, the pathogenic mechanisms underlying miR-9-1 downregulation and the RUNX1-RUNX1T1 fusion protein, generated from the translocation of t (8; 21) in AML, remain unclear. RUNX1-RUNX1T1 can induce leukemogenesis through resides in and functions as a stable RUNX1-RUNX1T1-containing transcription factor complex. In this study, we demonstrate that miR-9-1 expression increases significantly after the treatment of RUNX1-RUNX1T1 (1) AML cell lines with decitabine (a DNMT inhibitor) and trichostatin A (an HDAC inhibitor). In addition, we show that RUNX1-RUNX1T1 triggers the heterochromatic silencing of miR-9-1 by binding to RUNX1-binding sites in the promoter region of miR-9-1 and recruiting chromatin-remodeling enzymes, DNMTs, and HDACs, contributing to hypermethylation of miR-9-1 in t (8; 21) AML. Furthermore, because RUNX1, RUNX1T1, and RUNX1-RUNX1T1 are all regulated by miR-9-1, the silencing of miR-9-1 enhances the oncogenic activity of these genes. Besides, overexpression of miR-9-1 induces differentiation and inhibits proliferation in t (8; 21) AML cell lines. In conclusion, our results indicate a feedback circuitry involving miR-9-1 and RUNX1-RUNX1T1, contributing to leukemogenesis in RUNX1-RUNX1T1 (1) AML cell lines.
function of RUNX1 as an oncogene is necessary to sustain t (8; 21) AML and high expression of RUNX1 is associated with poorer outcomes in cytogenetically normal AML (CN-AML). 2 While the function of RUNX1 in t (8;21) AML has gradually begun to be understood, [3] [4] [5] the role of RUNX1T1 remains unclear despite the knowledge that it also works as an oncogene. 1, 6 In addition, functions of the RUNX1-RUNX1T1 fusion protein, such as arresting maturation, increasing cell survival and inhibiting differentiation, have been detected in hematopoietic cells. 7, 8 However, additional genetic and epigenetic abnormalities are likely required, because the presence of the RUNX1-RUNX1T1 fusion protein alone is not sufficient to induce leukemia. 9 MicroRNAs are short (18-22 nucleotides), endogenous, single-stranded, non-coding RNA molecules that are regarded as post-transcriptional regulators of gene expression. 10 In humans, miR-9 family have been identified as a tumor suppressor in cancers and there are three independent members (miR-9-1, miR-9-2 and miR-9-3). 11 The miR-9-1 plays an important role in the development of leukemia. [12] [13] [14] In t (8; 21) AML, miR-9-1 was revealed to be a downregulated and play a tumor suppressor miRNA. 9, 15 However, the link between downregulation of miR-9-1 and the presence of the RUNX1-RUNX1T1 fusion protein and their contribution to t (8; 21) AML need to be more thoroughly explored. 16, 17 A stable RUNX1-RUNX1T1-containing transcription factor complex directly induces leukemogenesis. 18 In this work, we demonstrate that RUNX1-RUNX1T1 triggers the heterochromatic silencing of miR-9-1 by binding to RUNX1-binding sites in the promoter region of miR-9-1. As a result, chromatin-remodeling enzymes, DNMTs and HDACs, are recruited to the gene. Silencing of miR-9-1 expression by epigenetic modification promotes the expression of its target genes, including RUNX1, RUNX1T1 and RUNX1-RUNX1T1, thus, contributing to leukemogenesis in t (8; 21) AML. Additionally, miR-9-1 had an important function of promoting differentiation in t (8; 21) AML cell lines.
Material and Methods

Cell lines and clinical samples
Kasumi-1 and SKNO-1 [myeloid leukemia cell line with the t(8;21) translocation], SKNO-1-siAE-RNA, U937 (monocytic leukemia cell line), and U937-AE-HA cell lines were maintained in RPMI 1640 medium supplemented with 50 mg/ml streptomycin, 50 IU penicillin and 10% fetal calf serum (FCS). We used the lentiviral vector pRRL.cPPT.hPGK to silence RUNX1-RUNX1T1 mRNA in SKNO-1 cells. The construction of this vector was described previously and the encoded the siAGF1 oligonucleotides (siAE-RNAs; sense, 5 0 -CCUCGAAAUCGUACUGAGAAG-3 0 ; antisense, 5 0 -UCU-CAGUACGAUUUCGAGGUU-3 0 ) bind to the fusion site of RUNX1-RUNX1T1.
19 U937 wild-type (WT) cells were electroporated with an HA-tagged RUNX1-RUNX1T1 cDNA and subcloned into a vector carrying the Zn 21 -inducible mouse MT-1 promoter to produce the U937-AE-HA clone. 20 Human embryonic kidney (HEK) 293T cells were cultured in DMEM supplemented with 50 mg/mL streptomycin, 50 IU penicillin, and 10% FCS. All AML patients is available at The Cancer Genome Atlas (TCGA) database.
RNA extraction and qRT-PCR
Total RNA was extracted from cells using the TriPure isolation system (Roche, Basel, Switzerland). The relative quantity of mature miR-9-1-5p was measured on 200 ng of total RNA by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) using the Hairpin-it miRNA qRT-PCR Quantitation kit (Genepharma, Shanghai, China) in the ABI PRISM 7500 sequence detection system (Applied Biosystems, Foster City, CA), and it was determined by the comparative CT method using snRNA U6 levels for normalization as recommended in the manufacturer's instructions.
Drugs treatment of cell lines
SKNO-1, SKNO-1-siAE, U937 and U937-AE cells were treated with DAC (0, 0.5 and 1 mM), and/or TSA (0, 10 and 20 nM), for 48 hr.
Bisulfite modification and genomic sequencing
The methylation status of the CpG dinucleotides within the regions relative to miR-9-1 (nucleotides 22,000 to 21) was analyzed. Genomic DNA (1 mg) from the indicated cell lines were used were treated with bisulfite, and the fragments of interest were amplified using EpiTect Bisulfite kit (Qiagen). Primer sequences are shown in Supporting Information Table  S1 . Purified PCR products were cloned into pGEM-T vectors (Promega), colony PCR was performed using vector-specific primers to detect positive clones, and the resulting vectors were sequenced for the analysis of DNA promoter methylation.
What's new? T (8;21), which is one of the most frequent chromosomal translocations in acute myeloid leukemia (AML), leads to the formation of the RUNX1-RUNX1T1 fusion transcription factor. The mechanisms underlying leukemogenesis however remain unclear.
Here, the authors show that RUNX1-RUNX1T1 triggers the heterochromatic silencing of miR-9-1, contributing to hypermethylation of miR-9-1 promoter in t (8; 21) AML. miR-9-1 silencing promotes the expression of target genes, including RUNX1, RUNX1T1 and RUNX1-RUNX1T1, which prevents differentiation and promotes proliferation of t (8; 21) AML. The results indicate a feedback circuitry involving miR-9-1 and RUNX1-RUNX1T1 contributing to leukemogenesis in t (8; 21) AML cell lines.
Transactivation assays
DNA fragments were amplified by PCR of human genomic DNA. Primer sequences are shown in Supporting Information Table S1 . All DNA fragments were inserted into the pGL3-LUC reporter vector (Promega Corp., Madison, WI). Mutants were generated using overlap-extension PCR. The SuperFect reagent (Qiagen, Hilden, Germany) was used to co-transfect HEK293T cells at a density of 2 3 10 5 with the pcDNA3 vectors (10, 50 or 100 ng) with or without the RUNX1-RUNX1T1 cDNA and plated in 24-well plates. The pRL-TK renilla luciferase reporter vector (Promega) served as a control. According to the manufacturer's instructions, cells harvested 48 hr after transfection were analyzed using the Dual-LuciferaseV R Reporter assay (Promega).
ChIP assays
Briefly, SKNO-1, SKNO-1-siAE, U937 and U937-AE cells were seeded at a density of 2 3 10 6 and incubated for 10 min at 378C to crosslink the proteins to DNA after treatment with formaldehyde (1% final concentration). Table S1 .
Reverse screening the miRNAs regulating RUNX1 and RUNX1T1 with luciferase assays
To screen the miRNAs that directly regulate the expression of RUNX1 and RUNX1T1, the 3'UTRs of the RUNX1 and RUNX1T1 genes were cloned into a modified pGL-3 control vector. The 3'UTRs were placed with all potential miRNA binding sites downstream of the coding sequence of luciferase. Luciferase assays were performed as previously described. 21 The transfection mixtures, which were derived from a constructed miRNA expression library, contained 100 ng of firefly luciferase reporter and 400 ng of plasmids expressing miR-9-1 primary transcripts. Transfection with pRL-TK (Promega) served as an internal control. The firefly luciferase activities, from 293T cells that were harvested 48 hr after transfection were assayed using the Dual-LuciferaseV R assay (Promega).
Immunoblot assays
Using the monoclonal the antibodies anti-RUNX1, anti-RUNX1T1, and anti-RUNX1-RUNX1T1 (Santa Cruz Biotechnology, Santa Cruz, CA), immunoblotting assays were performed on total cell lysates (50 mg). b-actin detection was used to normalize the amount of sample using anti-b-actin (Santa Cruz Biotechnology). The immunoreactivity was determined by the enhanced chemiluminescence method (Amersham Biosciences, Piscataway, NJ).
Cell proliferation, apoptosis and cell differentiation
Cell proliferation was evaluated by the CCK-8 (Dojindo, Japan), the concise instructions is that a minimum of 5,000 events a well cultured in 96-well plates was added to 10 lL of CCK-8 solution, and incubated for another 4 hr at 378C and 5% CO 2 atmosphere. Then, the absorbance was detected at 450 nm wavelength. The cell apoptosis assay was analyzed by a FACSCalibur flow cytometer (Becton Dickinson), the cells were collected for every sample for into BD falcon tube, stained with 2 lL Annexin V and 2 lL PI (BD Bioscience). Cell differentiation was also assessed by a FACSCalibur flow cytometer (Becton Dickinson), The samples stained with anti-CD11b (BD Bioscience, PharMingen) were analysed using CellQuest Pro software (Becton Dickinson).
Statistical analysis SPSS 13.0 software (SPSS, Chicago, IL) was used to process the data. All data are expressed as mean 6 standard deviation (SD) from at least three separate experiments. The Student's t test was used to determine the statistical significance of experimental results, and a p values 0.05 was considered significant.
Results
The expression of miR-9-1-5p is downregulated in RUNX1-RUNX1T1 (1) AML
To determine the role of RUNX1-RUNX1T1 in the regulation of miR-9-1-5p expression, RUNX1-RUNX1T1 was knocked out in SKNO-1 cells (SKNO-1-siAE) using a lentiviral vector, and HA-tagged RUNX1-RUNX1T1 cDNA was electroporated into U937 cells to produce the U937-AE-HA clone in a zincinducible manner. 20, 22 Knockdown and overexpression of RUNX1-RUNX1T1 by western blot in SKNO-1-siAE and U937-AE-HA were validated, respectively (Fig. 1a) . qRT-PCR revealed that miR-9-1-5p mRNA levels were higher in SKNO-1-siAE cells compared to SKNO-1 cells, and higher levels were discovered in U937 cells compared to U937-AE cells (Fig. 1b) . To verify these results, miR-9-1-5p mRNA levels were investigated from TCGA database obtained by whole-genome high-throughput sequencing. 23 This analysis confirmed that miR-9-1-5p was downregulated in RUNX1-RUNX1T1 (1) AML patients compared to RUNX1-RUNX1T1 (-) AML patients including seven CBFb-MYH11, 24 Complex karyotypes, seven MLL-translocation, 84 Normal karyotypes, 37 Others, 16 PML-RARa and seven RUNX1-RUNX1T1 (Fig. 1c) . Bioinformatics analysis (http://www.urogene.org/methprimer/) was used to predict that the promoter region of miR-9-1 contains a large number of CpGs islands (Supporting Information Fig. S1 ). To test whether DNA methylation and histone deacetylation account for the regulation of miR-9-1 expression, we treated SKNO-1 and U937-AE cells with a DNMT inhibitor, Decitabine (DAC), or/and HDAC inhibitor, trichostatin A (TSA), for 48 hr. Analysis of the qRT-PCR data from these experiments revealed that the expression levels of miR-9-1-5p were significantly increased in two cell lines by DAC or/and TSA alone in a dosedependent manner. This increase was especially prominent when DAC was used in combination with TSA (Fig. 1d) . For further confirm whether DNA methylation accounted for the regulation of miR-9-1 expression, we measured the frequency of methylated CpG dinucleotides encompassing the endogenous miR-9-1 gene sequences by genomic bisulfite sequencing in the following cell lines: SKNO-1, SKNO-1-siAE, U937, and U937-AE. The results confirmed that there are significant differences in the basal methylated states of these CpGs in SKNO-1 (90%), SKNO-1-siAE (54.4%), U937 (55.2%) and U937-AE (94.8%) cell lines (Supporting Information Fig. S2 ). These results indicate that DNA methylation and histone deacetylation may contribute to the transcriptional silencing of miR-9-1 in RUNX1-RUNX1T1 (1) cells. All of the primers sequences used in this work were shown in Supporting Information Table S1 .
RUNX1-RUNX1T1 protein localizes at an RUNX1-binding site and triggers the epigenetic silencing of the miR-9-1 genomic region A bioinformatics search (http://www.cbrc.jp/research/db/ TFSEARCH.html) revealed the presence of five putative RUNX1-binding sites surrounded by CpG islands in the miR-9-1 upstream region (nucleotides 22000 to 21, relative to miR-9-1) (Fig. 2a) . When luciferase reporter constructs, comprising sequences of the miR-9-1 regulatory region, were cotransfected with increasing amounts of RUNX1-RUNX1T1 into 293T cells, the transcription of miR-9-1 promoter resulted in a dose-dependent decrease in the luciferase reporter activity with all sequences containing functional, putative binding sites. Sequences with mutations or lacking a functional RUNX1 binding site had no significant effect on reporter activity levels, and no change in reporter activity was observed when empty vectors were co-transfected with the binding site sequences (Fig. 2b) . These results suggest that the proximal RUNX1 binding site (nucleotides at 2178) in the miR-9-1 putative regulatory region contributes to the RUNX1-RUNX1T1-dependent silencing of miR-9-1.
A chromatin immunoprecipitation (ChIP) assay was performed in SKNO-1, SKNO-1-siAE, U937 and U937-AE cells using anti-RUNX1, -RUNX1T1, -HDAC1, -DNMT1, -DNMT3a and -DNMT3b antibodies. The results revealed the presence of RUNX1-RUNX1T1, HDAC1, DNMT1, DNMT3a and DNMT3b at the miR-9-1 chromatin regulatory regions surrounding the proximal RUNX1-binding site (Figs. 2c and 2d) . Thus, the chromatin-remodeling complex was aberrantly formed by RUNX1-RUNX1T1, and the key regulatory mechanism for transcriptional silencing of miR-9-1 was mainly due to histone deacetylation and DNA methylation caused by HDAC1, DNMT1, DNMT3a and DNMT3b. Together, these results demonstrate that the RUNX1/RUNX1T1/DNMTs/HDACs corepressor complex regulates the expression of miR-9-1 and contributes to its silencing.
miR-9-1 inhibits RUNX1, RUNX1T1, and RUNX1-RUNX1T1
We used miRNA target prediction programs, such as Target Scan (http://www.targetscan.org) and miRanda (http://www. microrna.org), to predict target mRNA of miR-9-1. The results revealed that RUNX1 and RUNX1T1 are putative targets of miR-9-1 (Supporting Information Fig. S3 ). 293T cells co-transfected with the 3' UTRs of RUNX1 (wild-type, WT) and RUNX1T1 (WT) reporters and miR-9-1 exhibited significantly reduced luciferase activity compared to their mutants (Fig. 3a) . To examine the outcome of the luciferase reporter assay, western blotting analysis was performed. It is clear that cells transfected with miR-9-1 showed significantly reduced levels of RUNX1 or/and RUNX1T1 proteins compared with cells transfected with a scrambled control. (Fig.  3b, Supporting Information Fig. S4 ). The RUNX1-RUNX1T1 C-terminus has an approximately full-length RUNX1T1 and includes the 3'UTR. 24 Western blotting analysis indicated that the RUNX1-RUNX1T1 level was clearly reduced by the miR-9-1 (Fig. 3b, Supporting Information Fig. S4 ). Together, these results confirm that miR-9-1 regulates the expression of RUNX1, RUNX1T1 and RUNX1-RUNX1T1 by targeting the predicted binding sites.
Overexpression of miR-9-1 promotes differentiation and inhibits proliferation in t (8; 21) AML cell lines
To evaluate the effects of miR-9-1 in t (8; 21) AML, we transfected SKNO-1 with synthetic miR-9-1 and scramble, examined the cell differentiation and the cell growth curve by Flow cytometry analysis and the Cell Counting Kit-8 (CCK-8) assay, respectively. Flow cytometry showed that 100% SKNO-1 cells were labeled after 48 hrs transfection (Supporting Information Fig. S5A-S5C) . The miR-9-1-5p expression was increased in transfected miR-9-1 SKNO-1 cells compared with SKNO-1 cells (Supporting Information Fig. S5D ). The expression levels of CD11b which is myelomonocytic differentiation marker were increased and the growth was inhibited in transfected miR-9-1 cell lines compared with that in control ( Fig. 4a and 4b) . Then, we examined the biological effect of miR-9-1 on apoptosis using flow cytometry. It is no statistical differences among transfected SKNO-1 cells and control group (Fig. 4c) . From the above, miR-9-1 possibly has a key role to play in the regulation of cell differentiation and proliferation in t (8; 21) AML. Additionally, they indicate that a feedback minicircuitry composed of the RUNX1/ RUNX1T1/DNMTs/HDACs corepressor complex and miR-9-1 is present in t (8; 21) AML, contributing to leukemogenesis (Fig. 5) .
Discussion
The RUNX1-RUNX1T1 fusion transcription factor is generated by the chromosomal translocation, t (8; 21). The 8;21 translocation with breaks at 8q22 and 21q22.3. Chromosome 8 and 21 contains the RUNX1T1 gene and the RUNX1 gene, respectively. 25 Both human and mouse models of AML have demonstrated that the formation of RUNX1-RUNX1T1 is insufficient for leukemogenesis in the absence of secondary events. 26 In previous studies, we have shown that downregulation of miR-193a is another event controlling t (8; 21) AML. 20 MiR-9-1 is a member of miR-9 family that identified as a tumor suppressor in cancers. Because the promoter region of miR-9-1 contains more CpGs islands compared to miR-9-2 and miR-9-3, we chose miR-9-1 rather than miR-9-2 and miR-9-3, and speculated that miR-9-1 is more readily regulated by DNA methylation. Because miR-9-1 was shown to be a downregulated in t (8; 21) AML, we speculated that there will be a relationship between the expression of miR-9-1 and the RUNX1-RUNX1T1 fusion protein.
miR-9-1 has differential characteristics in the two facets of AML. On one hand, in AML with MLL rearrangements, miR-9-1 is a direct target of the MLL fusion protein and works as an oncogene. It plays an important role in the occurrence and progress of MLL rearrangements in AML. 12 On the other hand, in RUNX1-RUNX1T1 (1) AML, it was shown to be a downregulated. 15 The fact that miR-9-1 has differential roles in different types of AML clearly shows that the same gene may take on different roles due to different signaling pathways. Our studies demonstrated the silencing of miR-9-1 in RUNX1-RUNX1T1 (1) leukemia cell lines by the RUNX1/RUNX1T1/DNMTs/HDACs co-repressor. Thus, we speculated that reduced miR-9-1 levels may play an important role in the pathogenesis of t (8; 21) AML. Our results indicate that the presence of a feedback minicircuitry consisting of the RUNX1-RUNX1T1 fusion protein and miR-9-1 contributes to leukemogenesis.
Previous studies have shown that transcriptional or posttranscriptional alterations that reside in expression programming are likely responsible for leukemogenesis. 27 Ectopic epigenetic modifications, including histone-methylation, DNAmethylation or the dysregulation of miRNAs can result in altered transcription. 28 The RUNX1-RUNX1T1 fusion protein acts on the RUNX1 DNA-binding site in the upstream sequence of miR-223 by recruiting DNMTs and HDACs, resulting in the silencing of miR-223. 29 In this article, we show for the first time that RUNX1-RUNX1T1 recruits DNMTs and HDACs, leading to silencing of miR-9-1 in RUNX1-RUNX1T1 (1) AML. This explains how the RUNX1-RUNX1T1 fusion protein cooperates in the downregulation of miR-9-1 to contribute to leukemogenesis, and why the HDAC inhibitors used in the treatment of t (8; 21) AML have such efficacy.
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RUNX1 is a vital hematopoietic regulator, similar to miR-9-1, it has dual characteristics in AML. On one hand, RUNX1 is considered a tumor suppressor; for instance, previous studies have found that in activating mutations of RUNX1 have poor outcomes in cytogenetically normal AML. [31] [32] [33] [34] On the other hand, RUNX1 is an oncogene whose function depends on the level of its expression in t (8; 21)AML. Consequently, the inhibition of RUNX1 has been regarded as an effective treatment for t (8; 21) AML. 4, 5 While the RUNX1 gene has important dual roles in t(8; 21) AML, the function of RUNX1T1 remains controversial. 1, 6 Recent studies have shown that the RUNX1T1 protein works as an oncogenic protein and may have regulatory properties in leukemia cells. 6 Our studies show that the expression of miR-9-1 was decreased by methylation and deacetylation in t (8; 21) AML due to the expression of RUNX1-RUNX1T1. The levels of RUNX1, RUNX1T1, and RUNX1-RUNX1T1, which are all oncogenes and targeted by miR-9-1 in t (8; 21) AML, were increased. We also verified that miR-9-1 can promoting differentiation in t (8; 21) AML. The result is completely consistent with the published paper by Emmrich et al. 15 Thus, a feedback minicircuitry composed of the RUNX1/RUNX1T1/ DNMTs/HDACs corepressor and miR-9-1 is formed, which contributes to leukemogenesis in t (8; 21) AML.
Emmrich et al. showed that miR-9-1 exerts its tumor suppressor role in t (8; 21) AML through the cooperation with let-7 to repress the oncogenic LIN28B/HMGA2 axis. 15 Thus, miR-9-1 which acts in a stringent cell context-dependent role is a tumor suppressor in t (8; 21) AML.
It was recently also reported that NF-jB is regulated directly by miR-9-1, demonstrating that NF-jB is also a functionally important target of miR-9-1. When miR-9-1 is overexpressed, the levels of NF-jB are suppressed, whereas inhibition of miR-9-1 results in an increase in the NF-jB expression levels. 14, 35 We speculate that the imbalance of NFjB in t (8; 21) AML may also contribute to leukemogenesis.
In conclusion, we revealed the specific mechanism of downregulation of miR-9-1 in t (8; 21) AML through the RUNX1-RUNX1T1 recruitment of DNA silencing machinery, which contributes to leukemogenesis. In addition, we speculate that the upregulation of miR-9-1 may be a particularly effective target for the treatment of t (8; 21) AML.
